- Home
- MRVL vs TAK Comparison
MRVL vs TAK Comparison
Compare MRVL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVL
- TAK
- Stock Information
- Founded
- MRVL 1995
- TAK 1781
- Country
- MRVL United States
- TAK Japan
- Employees
- MRVL N/A
- TAK N/A
- Industry
- MRVL Semiconductors
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- MRVL Technology
- TAK Health Care
- Exchange
- MRVL Nasdaq
- TAK Nasdaq
- Market Cap
- MRVL 54.6B
- TAK 47.3B
- IPO Year
- MRVL 2000
- TAK N/A
- Fundamental
- Price
- MRVL $93.74
- TAK $13.44
- Analyst Decision
- MRVL Buy
- TAK
- Analyst Count
- MRVL 31
- TAK 0
- Target Price
- MRVL $94.68
- TAK N/A
- AVG Volume (30 Days)
- MRVL 16.8M
- TAK 2.8M
- Earning Date
- MRVL 12-02-2025
- TAK 10-30-2025
- Dividend Yield
- MRVL 0.26%
- TAK 4.04%
- EPS Growth
- MRVL N/A
- TAK N/A
- EPS
- MRVL N/A
- TAK 0.14
- Revenue
- MRVL $7,234,900,000.00
- TAK $29,846,840,032.00
- Revenue This Year
- MRVL $43.83
- TAK $0.14
- Revenue Next Year
- MRVL $16.02
- TAK $0.58
- P/E Ratio
- MRVL N/A
- TAK $190.43
- Revenue Growth
- MRVL 37.05
- TAK N/A
- 52 Week Low
- MRVL $47.09
- TAK $12.80
- 52 Week High
- MRVL $127.48
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- MRVL 64.04
- TAK 32.24
- Support Level
- MRVL $88.36
- TAK $12.99
- Resistance Level
- MRVL $91.51
- TAK $14.23
- Average True Range (ATR)
- MRVL 3.42
- TAK 0.13
- MACD
- MRVL 0.14
- TAK -0.04
- Stochastic Oscillator
- MRVL 79.34
- TAK 36.44
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.